Rhizopus microsporus as Causative Agent of Mucormycosis in COVID-19 Patient

Background: The pandemic of coronavirus disease (COVID-19) emerged as a fatal infection, especially in immunocompromised patients. Currently, this infection is managed with systemic corticosteroids. Co-infection of COVID- 19 with opportunistic fungi is increasingly recognized. Methods: We describe a case of rhino-cerebral mucormycosis 12 days following severe COVID-19 in a diabetic patient. Results: He received 50 mg amphotericin B and surgical debridement. The patient's symptoms improved following medical and surgical intervention. Conclusions: Mucormycosis is an uncommon but serious infection that complicates the course of severe COVID19. Subjects with diabetes mellitus and multiple risk factors may be at a higher risk for developing mucormycosis.

Automated summary

This case report describes a diabetic patient who developed rhino-cerebral mucormycosis 12 days after severe COVID-19. The patient's symptoms improved following medical and surgical intervention.